A new study by researchers at Stanford University and Ascend Clinical Laboratory and published in the journal The Lancet in September 2020 reports the prevalence of antibodies to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus in a dialysis patient population in the US.
